Treating older adults with advanced non-small cell lung cancer: A community cancer center experience

Journal of the American Geriatrics Society

Volumn 60, Issue 1, 2012, Pages 177-179

  Adonizio, Christian S ^a   Pope, Jane ^a   Frantz, Andrea ^a   Smego, Raymond A ^b  

^a Hematology and Oncology Associates of Northeastern Pennsylvania   (United States)

^b Janet Weis Children s Hospital   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADVANCED CANCER; AGED; CANCER CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LETTER; LUNG NON SMALL CELL CANCER; MALE; MONOTHERAPY; SCORING SYSTEM; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

EID: 84855836056     PISSN: 00028614     EISSN: 15325415     Source Type: Journal    
DOI: 10.1111/j.1532-5415.2011.03741.x     Document Type: Letter

References (9)

1. Davidoff AJ, Tang M, Seal B, et al. Chemotherapy and survival benefit in elderly patients with advanced non-small-cell lung cancer. J Clin Oncol 2010; 28: 2191-2197.
2. Edelman MJ, Tang M, Gardner JF, et al. Therapy of locally advanced NSCLC in the elderly: Analysis of 6,325 patients from Surveillance, Epidemiology, and End Results (SEER)-Medicare. ASCO. J Clin Oncol 2008; 26 (Suppl; abstract 7549).
3. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst 2003; 95: 362-372.
4. Cornella P, Frasca G, Carnicelli P, et al. Gemcitabine with either paclitaxel or vinorelbine versus paclitaxel alone for elderly or unfit advanced non-small cell lung cancer patients. Br J Cancer 2004; 91: 489-497.
5. Quoix EA, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet 2011; 378: 1079-1088.
6. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-2550; Erratum in: N Engl J Med 2007;356:318.
7. Schild SE, Stella PJ, Geyer SM, et al. The outcome of combined modality therapy for stage III non-small cell lung cancer in the elderly. J Clin Oncol 2003; 21: 3201-3206.
8. Jatoi A, Hillman S, Stella P, et al. Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group. J Clin Oncol 2005; 23: 9113-9119.
9. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: Implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst 2002; 94: 173-181.